Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.50 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.50 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.50 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.50 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.50 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.50 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.50 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | ACHE | P22303 | 4/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20595306 | 1.00 | TDP1 (0.55) | TDP1L3MBTL1ALDH1A1HDAC8HDAC3 | |
| SCHEMBL13884659 | 1.00 | TDP1 (0.55) | TDP1L3MBTL1ALDH1A1HDAC8HDAC3 | |
| SCHEMBL30041074 | 0.98 | TDP1 (0.53) | TDP1L3MBTL1ALDH1A1HDAC8HDAC3 | |
| SCHEMBL16068174 | 0.98 | TDP1 (0.53) | TDP1L3MBTL1ALDH1A1HDAC8HDAC3 | |
| SCHEMBL13509920 | 0.93 | ALDH1A1 (0.54) | TDP1L3MBTL1ALDH1A1MEN1CYP1A2 | |
| SCHEMBL29707271 | 0.93 | ALDH1A1 (0.54) | TDP1L3MBTL1ALDH1A1MEN1CYP1A2 | |
| SCHEMBL30999497 | 0.86 | GLS (0.52) | TDP1L3MBTL1ALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL13754582 | 0.86 | GLS (0.52) | TDP1L3MBTL1ALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL2604742 | 0.82 | TDP1 (0.75) | TDP1L3MBTL1HDAC8HDAC3HDAC4 | |
| SCHEMBL8862878 | 0.82 | TDP1 (0.75) | TDP1L3MBTL1HDAC8HDAC3HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4704915-A1 | LINKERS FOR DRUG CONJUGATES AND ANTIBODY DRUG CONJUGATES | BioAtla, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| WO-2024226567-A1 | LINKERS FOR DRUG CONJUGATES AND ANTIBODY DRUG CONJUGATES | BIOATLA, INC. (US) | 2024-10-31 | — | — | WO | disclosed |
| US-10434186-B2 | Functionalized linear ligands and complexes thereof | LUMIPHORE, INC. (US) | 2019-10-08 | — | — | US | disclosed |
| US-10434186-B2 | Functionalized linear ligands and complexes thereof | LUMIPHORE, INC. (US) | 2019-10-08 | — | — | US | disclosed |
| US-20170360956-A1 | FUNCTIONALIZED LINEAR LIGANDS AND COMPLEXES THEREOF | LUMIPHORE, INC. | 2017-12-21 | — | — | US | disclosed |
| US-20170360956-A1 | FUNCTIONALIZED LINEAR LIGANDS AND COMPLEXES THEREOF | LUMIPHORE, INC. | 2017-12-21 | — | — | US | disclosed |
| US-20170360956-A1 | FUNCTIONALIZED LINEAR LIGANDS AND COMPLEXES THEREOF | LUMIPHORE, INC. | 2017-12-21 | — | — | US | disclosed |
| EP-3237429-A1 | FUNCTIONALIZED LINEAR LIGANDS AND COMPLEXES THEREOF | Lumiphore, Inc. (US) | 2017-11-01 | — | — | EP | disclosed |
| WO-2016106241-A1 | FUNCTIONALIZED LINEAR LIGANDS AND COMPLEXES THEREOF | LUMIPHORE, INC. (US) | 2016-06-30 | — | — | WO | disclosed |
| WO-2016106241-A1 | FUNCTIONALIZED LINEAR LIGANDS AND COMPLEXES THEREOF | LUMIPHORE, INC. (US) | 2016-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170360956-A1 | FUNCTIONALIZED LINEAR LIGANDS AND COMPLEXES THEREOF | CLTB, CLTA, EPCAM | TDP1 3621/4885L3MBTL1 551/4885ALDH1A1 1477/4885 |
| US-10434186-B2 | Functionalized linear ligands and complexes thereof | CLTB, CLTA, EPCAM | TDP1 3621/4885L3MBTL1 551/4885ALDH1A1 1477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.